Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone in Patients Undergoing TAVI With Heart Failure
NCT07575672Phase 3Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Oct 2026
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of finerenone in heart failure with preserved ejection fraction (HFpEF), aortic stenosis (AS), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Oct 2026; status: recruiting.
02
Drugs
finerenone
03
Conditions
heart failure with preserved ejection fraction (HFpEF)aortic stenosis (AS)
Beyond the preview
Go deeper on NCT07575672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07575672.